

The DxH 690T also supports standardization across hospital networks to a single platform-DxH 900 for larger-volume labs and DxH 690T for mid-volume.” The DxH 690T reports high confidence results and improves turnaround time by reducing procedural steps and manual touchpoints, making it an ideal solution to help relieve some of this burden. “Managing increased demand for testing, while maximizing resource efficiency is top of mind for laboratorians even in the best of circumstances,” said Peter Soltani, Ph.D., senior vice president and general manager of the hematology business unit at Beckman Coulter. “For mid-volume labs, this is no exception.

ESId is a novel FDA-cleared, hematology-based cellular biomarker included as part of a standard CBC with differential, which is designed to help emergency department physicians identify adult patients with sepsis or at increased risk of developing sepsis. The DxH 690T brings mid-volume laboratories advanced features such as the Early Sepsis Indicator (ESId) available on Beckman Coulter’s larger high-volume analyzer, the DxH900. Hematology analysis is a critical part of triaging patients in urgent care settings. Designed to streamline workflow and minimize downtime in mid-volume laboratories, the DxH 690T delivers all of the benefits of the company’s flagship DxH 900 large-volume hematology analyzer in a table-top configuration. (Credit: PRNewswire / Beckman Coulter Diagnostics)īeckman Coulter announced the availability of its DxH 690T hematology analyzer in the U.S. The DxH 690T brings mid-volume laboratories advanced features such as the Early Sepsis Indicator (ESId) available on Beckman Coulter's larger high-volume analyzer, the DxH900īeckman Coulter’s DxH 690T haematology analyser.

High-Volume Performance in a Compact Design.
